Hemay808
/ Ganzhou Hemay Pharmaceutical
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
March 01, 2024
A Phase Ⅱ Study of Hemay808 for Atopic Dermatitis Patients
(clinicaltrials.gov)
- P2 | N=148 | Completed | Sponsor: Tianjin Hemay Pharmaceutical Co., Ltd | Unknown status ➔ Completed
Trial completion • Atopic Dermatitis • Dermatitis • Dermatology • Immunology
April 27, 2020
A Phase I Clinical Study of Hemay808
(clinicaltrials.gov)
- P1; N=42; Completed; Sponsor: Tianjin Hemay Pharmaceutical Co.,Ltd; Enrolling by invitation ➔ Completed
Clinical • Trial completion
April 27, 2020
A Phase Ⅱ Study of Hemay808 for Atopic Dermatitis Patients
(clinicaltrials.gov)
- P2; N=148; Recruiting; Sponsor: Tianjin Hemay Pharmaceutical Co.,Ltd; Not yet recruiting ➔ Recruiting
Clinical • Enrollment open • Atopic Dermatitis • Dermatitis • Dermatology • Dermatopathology • Immunology • Inflammation
April 20, 2020
A Phase Ⅱ Study of Hemay808 for Atopic Dermatitis Patients
(clinicaltrials.gov)
- P2; N=148; Not yet recruiting; Sponsor: Tianjin Hemay Pharmaceutical Co.,Ltd
Clinical • New P2 trial • Atopic Dermatitis • Dermatitis • Dermatology • Dermatopathology • Immunology • Inflammation
1 to 4
Of
4
Go to page
1